Ranolazine 500 mg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, University of Kansas Medical Center

Conditions

ALSAtherosclerotic Coronary Vascular Disease

Phase 2

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

TerminatedNCT01562041

Novartis PharmaceuticalsAtherosclerotic Coronary Vascular Disease

Start: 2012-03-09End: 2014-01-02Updated: 2021-06-18

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

CompletedNCT03472950

University of Kansas Medical CenterALS

Start: 2018-06-11End: 2022-12-09Updated: 2024-12-09